Diabetes in pregnancy: Management of diabetes and its complications from pre-conception to the postnatal period

NICE guidelines [CG63] Published date:

Consultation on review proposal with stakeholders: 07 March 2011 - 20 March 2011

Review decision date: May 2011

Review decision: 

This guideline is currently being updated. Further information can be found on the Diabetes in pregnancy guideline in development page.

This guidance has been updated and replaced by NICE guideline 3.


  • November 2014

    Units for reporting HbA1c have changed from % to mmol/mol since this guideline was published. The NICE Pathway on diabetes has been changed to reflect this. The guideline is being updated and the new version (to be published in 2015) will use mmol/mol.

    July 2008

    Since publication, the information on the therapeutic indications, contraindications and use in pregnancy and lactation of drugs used in diabetes management and retinal assessment (specifically insulins, the oral hypoglycaemic agents metformin and glibenclamide, and tropicamide) has been corrected to follow the relevant summaries of product characteristics (SPCs) (July 2008). Changes have been made to the NICE guideline, the full guideline and the quick reference guide.

    'The recommendation on the use of the rapid-acting insulin analogues aspart and lispro in pregnant women with diabetes (this is recommendation in the NICE guideline) is now as follows:

    Healthcare professionals should be aware that data from clinical trials and other sources do not suggest that the rapid-acting insulin analogues (aspart and lispro) adversely affect the pregnancy or the health of the fetus or newborn baby.

    The electronic versions of the guideline on this website all contain the correct information on drugs used in diabetes management and retinal assessment. Hard copies of the corrected quick reference guide are being mailed to the NHS.

    The Understanding NICE guidance booklet does not give all details of the information healthcare professionals need to consider when prescribing insulin and other drugs used to manage diabetes or for retinal assessment in women who are pregnant or breastfeeding. Therefore it did not require any changes to reflect the reissued guideline on diabetes in pregnancy and has not been reissued.


  • Get involved